Wearable Glucose Monitors Go Mainstream — Without a Prescription

Abbott Lingo and Dexcom Stelo are now over-the-counter. What the data actually tells healthy users about diet and sleep.

Over-the-counter continuous glucose monitors are now a billion-dollar consumer category, and the inflection happened almost without a marketing event sharp enough to date it. Abbott's Lingo and Dexcom's Stelo cleared the FDA's de novo pathway for non-diabetic wellness use.

The underlying sensor technology has finally crossed the cost threshold where mass deployment is economically rational. Enzymatic glucose-oxidase electrodes are now produced on lines that look closer to semiconductor backend assembly than traditional medical-device manufacturing.

The behavioral science underneath the data stream is where the category gets philosophically uncomfortable. Continuous biometric feedback turns out to be a powerful behavior-modification substrate, and not always in the direction the user intended.

The forward question is whether the FDA continues to treat non-diabetic CGM use as a wellness category or starts demanding clinical-grade outcome data. Either resolution is consequential. The version of consumer health that emerges in 2028 will not look like the version that walked into 2025.